A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer.

Trial Profile

A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 May 2015

At a glance

  • Drugs Cabozantinib (Primary) ; Mitoxantrone; Prednisone
  • Indications Bone metastases; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms COMET-2
  • Sponsors Exelixis
  • Most Recent Events

    • 19 Feb 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov
    • 01 Dec 2014 Results published in an Exelixis media release.
    • 01 Dec 2014 Primary endpoint has not been met (confirmed pain response at Week 12 durable since Week 6), according to an Exelixis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top